Clinical Trial Update: Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

View source ↗

Summary

The study aims to use microbiome profiles to predict toxicity from Durvalumab after chemoradiation in stage III non-small cell lung cancer. The trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Jun Zhang, MD, PhD | Conditions: NSCLC, Stage III, Locally Advanced Lung Carcinoma | Status: RECRUITING